MSB 2.10% $1.17 mesoblast limited

Ann: Mesoblast Update on COVID-19 ARDS Trial, page-232

  1. 986 Posts.
    lightbulb Created with Sketch. 390
    you can overlook a few failures...but regular failures points to managements incompetence..unfortunately too many shareholders have been burnt and it will be difficult to regain investor trust.
    MSB will now become a traders platform until some form of success is achieved.
    i do believe in the technology..but poorly designed trials and non compliance with FDA requirements has caused failures...as much as i thought the class action against MSB was a joke, i am now thining twice about their merits and likelihood of their success.
    good luck to all
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.